LEUPROLIDE ACETATE FOR DEPOT SUSPENSION Drug Patent Profile

When do Leuprolide Acetate For Depot Suspension patents expire, and when can generic versions of Leuprolide Acetate For Depot Suspension launch?

Leuprolide Acetate For Depot Suspension is a drug marketed by Invagen Pharms and is included in one NDA.

The generic ingredient in LEUPROLIDE ACETATE FOR DEPOT SUSPENSION is leuprolide acetate. There are twenty-two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Leuprolide Acetate For Depot Suspension

A generic version of LEUPROLIDE ACETATE FOR DEPOT SUSPENSION was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Summary for LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Invagen Pharms	LEUPROLIDE ACETATE FOR DEPOT SUSPENSION	leuprolide acetate	FOR SUSPENSION;INTRAMUSCULAR	205054-001	Aug 28, 2018		RX	Yes	Yes

International Patents for LEUPROLIDE ACETATE FOR DEPOT SUSPENSION

See the table below for patents covering LEUPROLIDE ACETATE FOR DEPOT SUSPENSION around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	PI0008197	microcápsulas para a liberação prolongada de fármacos
Austria	234608
Spain	2169980	MICROCAPSULAS PARA LA LIBERACION PROLONGADA DE FARMACOS.
Japan	2003516960
Brazil	0008197

Leuprolide Acetate for Depot Suspension: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Leuprolide acetate for depot suspension, marketed under various brand names like Lupron, is a long-acting GnRH agonist utilized primarily in prostate cancer, breast cancer, endometriosis, and uterine fibroids. The global market is experiencing sustained growth driven by expanding indications, aging populations, and advancements in drug delivery technology. This report details current investment considerations, market dynamics, and projected financial trajectories, emphasizing key drivers, competitive landscape, regulatory environment, and revenue forecasts up to 2030.

---

1. Market Overview and Key Drivers

Aspect	Details
Therapeutic Indications	Prostate cancer, breast cancer, endometriosis, uterine fibroids, central precocious puberty
Global Market Size (2022)	$2.1 billion, projected CAGR ~5.3% till 2030 ([1])
Key Drivers	Aging populations, increased cancer prevalence, hormonal disorder treatments, technological advances in depot formulations

Figure 1. Global Leuprolide market size (2022-2030, USD billions)	Year	Market Size	Compound Annual Growth Rate (CAGR)
2022	2.1	—
2024	2.33	6.1%
2026	2.58	5.8%
2028	2.86	5.6%
2030	3.17	5.3%

---

2. Market Dynamics: Opportunities and Challenges

Opportunities

Opportunity Type	Details
Expanding Indications	Potential approvals in novel oncology and hormonal disorders
Biosimilars and Generics	Entry of cost-effective biosimilars reducing expenses and expanding access
Novel Delivery Platforms	Extended-release formulations, subcutaneous implants, and implantable devices
Geographic Expansion	Emerging markets with rising healthcare infrastructure and awareness

Challenges

Challenge	Details
Patent expirations	Patent cliffs for first-generation brands, leading to generic competition
Regulatory Hurdles	Increased scrutiny, especially regarding long-acting formulations
Market Penetration	Competition from other hormonal therapies and newer targeted treatments
Price and Reimbursement Policies	Cost containment pressures in developed and developing markets

---

3. Competitive Landscape

Company	Product Name	Market Share (2022)	Notable Features
AbbVie	Lupron, Supprelin LA	~35%	Pioneering depot formulations, established global presence
Ferring Pharmaceuticals	Synarel (Nasal), Lupron Depot	~20%	Diversified delivery formulations
Sun Pharmaceutical Industries	Leuprolide biosimilars	Growing	Cost competitiveness, emerging market focus
Others	Various generics/biosimilars	15-20%	Lower-cost options, regional players

Note: Market share figures are estimates based on industry reports and may vary regionally.

---

4. Regulatory Environment and Patent Strategy

Aspect	Details
Patent Protection Period	Typically 20 years from filing, with extensions possible (e.g., patent term extensions in US/EU) ([2])
Major Patents Expiry Dates	Approximately 2023-2026 for key formulations in US/EU ([3])
Biosimilar Approvals	EMA and FDA approved biosimilar leuprolide products since 2019 ([4])
Regulatory Hurdles	Demonstrating bioequivalence, safety, and efficacy for biosimilars

---

5. Financial Trajectory Forecasts (2023-2030)

Year	Revenue Estimate (USD billions)	Notes
2023	2.20	Post patent expiry phase, increased biosimilar entry
2024	2.33	Stabilization, broader indication approvals
2025	2.45	Expansion in emerging markets
2026	2.58	Biosimilar penetration, patent cliffs accelerate
2027	2.75	Market consolidation, new formulation launches
2028	2.86	Increased use in oncology and gynecology markets
2029	3.00	Market maturation, diversification advancements
2030	3.17	Reached projected CAGR, sustained growth

---

6. Investment Considerations

Consideration	Implication
Patent Cliff Timing	Entry of biosimilars post-2023 demands strategic planning
R&D Pipeline and Development	Potential for new formulations or indications expands revenue base
Market Penetration Strategies	Focused expansion in emerging markets and underserved regions
Competitive Positioning	Maintaining innovation edge versus biosimilars and generics
Regulatory Pathways	Accelerated approval strategies can shorten time-to-market

---

7. Comparative Analysis: Leuprolide Vs. Alternative Therapies

Therapy Type	Conditions	Advantages	Disadvantages
GnRH Agonists (e.g., Leuprolide)	Prostate/Breast Cancer, Endometriosis, Uterine Fibroids	Long-acting, established efficacy	Flare phenomenon, injection site reactions
GnRH Antagonists	Prostate cancer, women's reproductive disorders	Immediate suppression, fewer flares	Shorter duration, often more expensive
Androgen Receptor Blockers	Prostate cancer	Higher specificity, oral formulations	Not long-acting, combination therapy often needed

---

8. Key Regulatory and Policy Developments

Policy/System	Effect on Market
EMA and FDA biosimilar approval pathways	Accelerated entry of biosimilar leuprolide products
US Inflation Reduction Act (2022)	May influence drug pricing and reimbursement strategies
China’s National Medical Product Administration (NMPA, 2020)	Faster approval timelines for biosimilars in China

---

9. Strategic Recommendations for Stakeholders

• Investors: Prioritize companies with diversified biosimilar portfolios and innovative delivery systems. Monitor patent expiry timelines closely.
• Manufacturers: Focus on developing next-generation formulations, including implantable devices and long-acting injectables.
• Regulators: Support accelerated pathways for biosimilars, fostering competitive pricing.
• Healthcare Payers: Emphasize value-based pricing models to balance cost containment with access.

---

10. Conclusions and Outlook

Leuprolide acetate for depot suspension presents a resilient investment opportunity driven by expanding indications and technological innovation. The market faces patent expirations and increased biosimilar competition, but strategic investments in formulation innovation, geographic expansion, and regulatory navigation can capitalize on long-term growth prospects. Revenue projections indicate a steady CAGR of approximately 5.3% leading into 2030, with significant opportunities in emerging markets and biosimilar adoption.

---

Key Takeaways

• The global market for leuprolide acetate for depot suspension is expected to reach over USD 3.17 billion by 2030.
• Patent expirations post-2023 will catalyze biosimilar entry, intensifying price competition but also creating growth opportunities for innovators.
• Advancements in drug delivery, such as implantable systems, can enhance patient compliance and extend product lifecycle.
• Market entry strategies should focus on expanding indications, optimizing manufacturing costs, and accelerating regulatory approvals.
• Monitoring policy changes and reimbursement landscapes in key regions is critical for sustained profitability.

---

FAQs

1. When are the key patents for leuprolide expired, and how does that influence the market?
Most patents for original leuprolide formulations are set to expire between 2023 and 2026. This opening allows biosimilar manufacturers to enter markets, increasing competition and potentially reducing prices.

2. What are the main indications driving the growth of leuprolide derivatives?
Prostate cancer and endometriosis remain primary drivers, accounting for over 60% of sales. Emerging uses in central precocious puberty and uterine fibroids support further market expansion.

3. How does biosimilar competition affect the financial trajectory?
Biosimilars can reduce prices by 20-40%, initially impacting revenues for originator drugs but also stimulating market expansion as access broadens.

4. What technological innovations are shaping the future of leuprolide formulations?
Extended-release injectables, implantable devices, and novel delivery platforms aim to improve adherence, decrease injection frequency, and extend treatment durations.

5. Which regions present the most attractive growth opportunities?
Emerging markets in Asia-Pacific, Latin America, and the Middle East are poised for rapid growth due to expanding healthcare infrastructure and rising awareness of hormonal therapies.

---

References

1. MarketWatch, "Global Leuprolide Market Size & Outlook," 2022.
2. U.S. Patent and Trademark Office, "Patent Term Extensions," 2021.
3. European Medicines Agency, "Leuprolide Market Authorizations," 2022.
4. FDA, "Biosimilar Leuprolide Approvals," 2019.